Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a human Fc enhanced next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, which is being developed by CTEP as an anticancer agent in collaboration with Agenus Inc. CTEP will also consider requests to supply botensilimab for nonclinical studies. All clinical and nonclinical researchers interested in working with the agent are welcome to apply. All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
今天，艾吉纳斯公司（"艾吉纳斯"）（纳斯达克：AGEN）是开发新型免疫治疗癌症代理方面的领导者。该公司今天宣布，癌症治疗评估计划（CTEP）正在接受意向书（LOIs）以使用botensilimab（BOT）进行临床研究，BOT是一种人Fc增强的下一代抗胞毒性T淋巴细胞相关蛋白4（CTLA-4）抗体。CTEP正在与Agenus Inc.合作，将BOT作为抗癌药物开发。CTEP还将考虑提供botensilimab用于非临床研究。所有对与该药物合作感兴趣的临床和非临床研究人员都可以申请。CTEP批准的所有建议都将发送给行业合作伙伴，以确认提供研究所需药物。